Comparing Gonadotropins for IVF: Live Birth Rates and OHSS Risk

Recent clinical data current to March 2025 indicates that the choice of gonadotropin for ovarian stimulation in in vitro fertilisation (IVF) significantly influences both live birth rates and the risk of ovarian hyperstimulation syndrome (OHSS). According to a comprehensive review of 59 studies encompassing 18,119 participants, the efficacy of these hormones varies, with recombinant follicle-stimulating hormone (rFSH) showing differences in live birth rates and OHSS risk compared to other gonadotropins.

Key Clinical Takeaways:

• Evidence suggests live birth rates are statistically higher with HMG/HP-HMG compared to rFSH, while rFSH demonstrates improved outcomes over lower-cost biosimilars.
• The risk of OHSS—a potentially severe complication where ovaries swell and fluid leaks into the abdomen—is lower when using HMG/HP-HMG or follitropin delta compared to rFSH.
• Clinical decision-making should prioritize personalized protocols, as current research indicates limited efficacy differences between rFSH, FSH-HP, and follitropin delta.

Comparative Efficacy of Gonadotropin Protocols

The selection of gonadotropins represents a critical variable in the pathogenesis of successful IVF cycles. According to a comprehensive review of 59 studies encompassing 18,119 participants, the efficacy of these hormones is not uniform. When comparing rFSH to HMG/HP-HMG, researchers observed that the former is associated with a probable decrease in live births. Specifically, if the baseline chance of a live birth with HMG/HP-HMG is 28%, the probability with rFSH shifts to a range between 22% and 27%.

This variance necessitates a nuanced approach to treatment planning. Patients seeking to optimize their cycle outcomes should consult with reproductive endocrinologists who can interpret these statistical probabilities within the context of individual patient profiles. The reliance on pharmaceutical-sponsored studies remains a point of contention, as potential bias in trial design may influence reported success rates. Clinicians must balance these findings against the patient’s specific ovarian reserve and history of response to controlled ovarian stimulation.

Managing the Risk of Ovarian Hyperstimulation Syndrome

OHSS remains a primary morbidity concern in assisted reproductive technology. The data confirms that rFSH is associated with a higher risk of OHSS compared to both HMG/HP-HMG and follitropin delta. For instance, while the risk of OHSS with HMG/HP-HMG stands at approximately 2.6%, the administration of rFSH elevates that risk to between 2.9% and 4.7%. This differential is clinically significant for women at high risk of hyper-response, such as those with polycystic ovary syndrome (PCOS).

The development of follitropin delta—a recombinant hormone designed for personalized dosing—seeks to mitigate such risks. However, current evidence indicates that rFSH still carries a higher risk profile when compared directly against this personalized agent. Addressing these risks requires rigorous monitoring protocols. Specialized fertility clinics utilizing advanced ultrasound and serum hormone tracking are essential for identifying early indicators of OHSS and adjusting gonadotropin dosages in real-time to prevent severe complications.

Clinical Considerations for Biosimilars and Future Research

As healthcare systems face increasing pressure to manage the cost of fertility treatments, biosimilars have emerged as a viable alternative to branded rFSH. The evidence suggests that rFSH likely provides higher live birth rates and clinical pregnancy rates compared to these manufactured alternatives. However, the data regarding OHSS risk between rFSH and biosimilars remains inconclusive, with current studies suggesting little to no significant difference.

The pharmaceutical industry’s role in funding the majority of these comparative trials underscores the need for independent, longitudinal research. Future investigations must shift focus toward cumulative outcomes across multiple frozen embryo transfer cycles rather than relying solely on fresh embryo transfer metrics, which dominate the current evidence base. For clinical practices and pharmaceutical procurement officers, navigating these shifts requires a commitment to evidence-based medicine that prioritizes both patient safety and long-term success rates over short-term cost savings.

The trajectory of fertility medicine is moving toward increasingly personalized hormone regimens. As the field advances, the integration of precise gonadotropin titration will likely refine these outcomes further. Patients and providers are encouraged to remain informed of the latest clinical guidance to ensure that treatment protocols are aligned with the most robust, peer-reviewed evidence available.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.